Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 5/20 | 0.43 |
| ▸ | ITK | Q08881 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954931 | 0.85 | RORC (0.41) | SYKRORCITKEGFRNAMPT | |
| SCHEMBL31221957 | 0.84 | MAPKAPK2 (0.40) | SYKRORCNAMPTMAP4K4AR | |
| SCHEMBL15081332 | 0.81 | SYK (0.45) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL29813612 | 0.81 | SYK (0.45) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL30004261 | 0.80 | SYK (0.44) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL29509761 | 0.80 | SYK (0.44) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL25898751 | 0.80 | SYK (0.44) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL2015768 | 0.80 | SYK (0.44) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL29178680 | 0.80 | SYK (0.44) | SYKRORCNAMPTEGLN2MAP4K4 | |
| SCHEMBL25394963 | 0.79 | BTK (0.37) | SYKITKEGFRMAP4K4TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | NIHON NOHYAKU CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4495114-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | Nihon Nohyaku Co., Ltd. (JP) | 2025-01-22 | — | — | EP | disclosed |
| CN-118922417-A | Azole compounds and antifungal agents | 日本农药株式会社 | 2024-11-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197384-A1 | AZOLE COMPOUND AND ANTIFUNGAL AGENT | CBR3, ERG28, CBR1 | SYK 1141/4885RORC 459/4885ITK 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.